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Figure 1. The interactive tool (intervention, available at http://lse.staging.kiln.digital/statins/) shows the overall ranking of 5 
statins from best to worst in terms of 3 benefit outcomes (all-cause mortality, coronary events, and cerebrovascular events) 
and 4 harm outcomes (muscle pain, kidney enzyme elevations, liver enzyme elevations, and discontinuations because of 
other adverse events).  Users can specify the relative importance of different outcomes by moving the cursors from not 
important to very important. Different colours correspond to different outcomes, the height of the bars corresponds to the 
relative weight put on each outcome, and the width of the bars corresponds to the probability that statin is the best on that 
outcome. The data visualization is dynamic and the overall ranking of individual statins changes depending on user 
preferences. For example, (A) simvastatin ranks as the best option when the user specifies that all-cause mortality is the only 
important outcome; (B) pravastatin is the best treatment option when the user specifies kidney enzyme elevations as the 
only important outcome; and (C) simvastatin ranks best when the user considers all-cause mortality to be the most important 
outcome followed by coronary events and cerebrovascular events, which are in turn more important than all harm end 
points. 
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Figure 2. CONSORT Flowchart (9) 
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Table 1. Background Informationa 
 
Intervention 
(n = 122) 
Control  
(n = 136) 
Total 
(n = 258) p value 
        
Age (years)b 32.3 (8.8) 32.62 (9.32) 32.44 (9.08) 0.754 
Gender        
    Male 76 (62.3) 85 (62.5) 161 (62.4) 0.792 
    Female 45 (36.9) 51 (37.5) 96 (37.2)  
    Other 1 (0.8) 0 (0) 1 (0.4)  
Ethnicity        
    White 89 (73.0) 92 (67.6) 181 (70.2) 0.326 
    Black or African American 6 (4.9) 13 (9.6) 19 (7.4)  
    Hispanic 8 (6.6) 11 (8.1) 19 (7.4)  
    Asian 15 (12.3) 19 (14.0) 34 (13.2)  
    American Indian or  
    Native Alaskan 1 (0.8) 1 (0.7) 2 (0.8)  
    Other 3 (2.5) 0 (0) 3 (1.2)  
Education        
    Less than high school 0 (0) 1 (0.7) 1 (0.4) 0.160 
    High school degree 31 (25.4) 38 (27.9) 69 (26.7)  
    Associate degree 19 (15.6) 33 (24.3) 52 (20.2)  
    Bachelor degree 63 (51.6) 52 (38.2) 115 (44.6)  
    Graduate degree 9 (7.4) 12 (8.8) 21 (8.1)  
Income ($)        
    Less than 20,000 25 (20.5) 26 (19.1) 51 (19.8) 0.611 
    20,000 to 34,999 33 (27.0) 33 (24.3) 66 (25.6)  
    35,000 to 49,999 32 (26.2) 29 (21.3) 61 (23.6)  
    50,000 to 74,999 20 (16.4) 31 (22.8) 51 (19.8)  
    75,000 to 99,999 7 (5.7) 13 (9.6) 20 (7.8)  
    100,000 to 149,999 4 (3.3) 4 (2.9) 8 (3.1)  
    150,000 or more 1 (0.8) 0 (0) 1 (0.4)  
Has cardiovascular disease?        
     No 113 (92.6) 122 (89.7) 235 (91.1) 0.513 
     Yes 9 (7.4) 14 (10.3) 23 (8.9)  
At high risk for cardiovascular  
disease?       
     No 108 (88.5) 113 (83.1) 221 (85.7) 0.286 
     Yes 14 (11.5) 23 (16.9) 37 (14.3)  
Talked to a doctor about  
statins?        
     No 107 (87.7) 112 (82.4) 219 (84.9) 0.296 
     Yes 15 (12.3) 24 (17.6) 39 (15.1)  
Currently or previously  
prescribed statins?       
     No 113 (92.6) 124 (91.2) 237 (91.9) 0.820 
     Yes 9 (7.4) 12 (8.8) 21 (8.1)  
a Values are presented as number and proportions unless stated 
b Mean and standard deviation reported 
 
 
 
Figure 3. Participants ratings of the importance of each of the benefits and harms associated with statins. The 
differences in ratings across the outcomes indicate that participants have differing preferences for the possible 
outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 2. Self-reported decision conflict, decision self-efficacy, and preparation for decision makinga 
 
Intervention 
(n = 122) 
Control  
(n = 136) 
Mean Difference 
(95% CI) p value 
Decisional Conflict 
Scale 14.59 (15.04) 23.13 (20.34) -8.53 (-12.96, -4.11) 0.001 
        
Decision Self-Efficacy 
Scale 82.86 (10.56) 82.4 (9.96) 0.46 (-2.06, 2.98) 0.360 
        
Preparation for 
Decision Making Scale 96.11 (18.07) 91.91 (18.04) 4.19 (-0.24, 8.63) 0.031 
a Values are presented as means and standard deviations 
 
 
 
 
 
 
Figure 4. Comparison of first ranked statins with charts and subsequent ranking with the interactive tool in participants 
randomized to the intervention group (n = 122). Ranking with the charts is shown on the left and ranking with the interactive 
tool on the right (Diagram created using SankeyMATIC). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ranked 1st 
Lovastatin (n=3) 
Pravastatin (n=5) 
Rosuvastatin (n=1) 
Simvastatin (n=101) 
Atorvastatin (n=12) 
Rosuvastatin (n=7) 
Simvastatin (n=76) 
Atorvastatin (n=22) 
Pravastatin (n=11) 
Lovastatin (n=6) 
 
 
 
Table 3. Acceptability of the interactive toola 
 Total (n = 258) 
Presentation of information on …  Very poor     Poor    Neutral     Good Very Good 
           
How to use the tool 2 (0.8) 15 (5.8) 23 (8.9) 122 (47.3) 96 (37.2) 
The possible benefits and harms 4 (1.6) 15 (5.8) 47 (18.2) 114 (44.2) 78 (30.2) 
The range of statins available 3 (1.2) 10 (3.9) 37 (14.3) 114 (44.2) 94 (36.4) 
The benefits and harms of each statin 4 (1.6) 26 (10.1) 35 (13.6) 120 (46.5) 73 (28.3) 
How the statins compare to each 
other 0 (0) 8 (3.1) 23 (8.9) 104 (40.3) 123 (47.7) 
           
The tool presented …          
Too much information 59 (22.9)         
The right amount of information 184 (71.3)         
Not enough information 15 (5.8)         
           
The information is …           
Biased toward the benefits of statins 19 (7.4)         
Balanced 196 (76.0)         
Biased towards the harms of statins 43 (16.7)         
           
How likely would you be to use the tool if it was 
freely available?         
Very unlikely 5 (1.9)         
Unlikely 10 (3.9)         
Neither 35 (13.6)         
Likely 112 (43.4)         
Very Likely 96 (37.2)         
a Values are presented as number and proportion of participants 
